Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Lancet Neurol. 2010 Oct;9(10):978–985. doi: 10.1016/S1474-4422(10)70184-8

Table 3.

Population attributable risk percent and odds ratios associated with the chromosome 9p21 risk haplotype carrier status and with homozygous D90A SOD1 allele status among the Finnish population.*

Familial ALS samples
(n = 93)
 Sporadic ALS samples
(n = 312)
 All ALS samples
(n = 405)
Locus PAR% (95% CI) OR (95% CI) PAR% (95% CI) OR (95% CI) PAR% (95% CI) OR (95% CI)
9p21 risk haplotype 37·9% (27·7–48·1%) 21·0 (11·2–39·1) 9·9% (6·6–13·2%) 5·9 (3·4–10·3) 13·0% (9·9–16·1) 9·0 (5·0–14·3)
Homozygous D90A 25·5% (16·9–34·1%) 202·9 (27–1518) 2·8% (1·0–3·9%) 21·6 (2·8–166) 5·6% (3·8–7·4%) 54·4 (7·4–397)
Both 64·9% (54·6–75·2%) 58·4 (30·9–110·4) 12·8% (9·2–16·5%) 7·3 (4·3–12·4) 19·6% (15·8–23·4%) 12·6 (7·6–20·8)
*

Calculations were based on 27 familial ALS cases and 13 sporadic ALS cases that were homozygous carriers of the SOD1 D90A allele, and on 41 familial ALS cases and 58 sporadic ALS cases that carried the chromosome 9p21 risk haplotype and were not homozygous D90A carriers. PAR% = population attributable risk percent; OR = odds ratio; 95% CI = 95% confidence interval; 9p21 risk haplotype refers to carrier status for the 42-SNP risk haplotype identified on chromosome 9p21; Homozygous D90A refers to homozygous carrier status for the D90A allele of the SOD1 gene on chromosome 21q22; “Both” refers to the combined effects of the 9p21 risk haplotype and homozygous D90A allele carrier status.